The Challenging Clinical Management of Patients with Cranial Dural Arteriovenous Fistula and Secondary Parkinson's Syndrome: Pathophysiology and Treatment Options.


Journal

Cerebrovascular diseases extra
ISSN: 1664-5456
Titre abrégé: Cerebrovasc Dis Extra
Pays: Switzerland
ID NLM: 101577885

Informations de publication

Date de publication:
2020
Historique:
received: 13 05 2020
accepted: 13 07 2020
pubmed: 23 10 2020
medline: 27 1 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Cranial dural arteriovenous fistula (cDAVF) may rarely lead to parkinsonism and rapid cognitive decline. Dysfunction of the extrapyramidal system and the thalamus, due to venous congestion of the Galenic system with subsequent parenchymal edema, is likely to represent an important pathophysiological mechanism. Here, we report a case of a 57-year-old man with a cDAVF of the straight sinus (Borden type III; DES-Zurich bridging vein shunt [BVS] type with direct, exclusive, and strained leptomeningeal venous drainage [LVD]) and subsequent edema of both thalami, the internal capsule, the hippocampi, the pallidum, and the mesencephalon. Several attempts at venous embolization were unsuccessful, and the neurological condition of the patient further deteriorated with progressive parkinsonism and intermittent episodes of loss of consciousness (KPS 30). A suboccipital mini-craniotomy was performed and the culminal vein was disconnected from the medial tentorial sinus, achieving an immediate fistula occlusion. Three-month follow-up MRI revealed complete regression of the edema. Clinically, parkinsonism remitted completely, allowing for tapering of dopaminergic medication. His cognition markedly improved in further course. The purpose of this report is to highlight the importance of rapid and complete cDAVF occlusion to reverse venous hypertension and prevent progressive clinical impairment. The review of the literature underlines the high morbidity and mortality of these patients. Microsurgical disconnection of the fistula plays an important role in the management of these patients and, surprisingly, has not been reported so far.

Identifiants

pubmed: 33091906
pii: 000510597
doi: 10.1159/000510597
pmc: PMC7670372
doi:

Substances chimiques

Antiparkinson Agents 0

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-138

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Author(s) Published by S. Karger AG, Basel.

Références

J Neuroimaging. 2009 Apr;19(2):183-4
pubmed: 18681932
Neurol India. 2014 Jan-Feb;62(1):107-10
pubmed: 24608486
J Neurosurg. 1995 Feb;82(2):166-79
pubmed: 7815143
Eur J Neurol. 2005 May;12(5):403-6
pubmed: 15804274
J Stroke Cerebrovasc Dis. 2012 Oct;21(7):619.e3-5
pubmed: 21376630
World Neurosurg. 2019 Jan;121:e543-e553
pubmed: 30268554
Rinsho Shinkeigaku. 1998 Feb;38(2):112-7
pubmed: 9619072
Neurosurg Rev. 2015 Apr;38(2):265-71; discussion 272
pubmed: 25403687
BMJ Case Rep. 2014 Jun 02;2014:
pubmed: 24891481
Neurosurg Rev. 2015 Apr;38(2):283-91; discussion 291
pubmed: 25421555
Medicine (Baltimore). 2017 Dec;96(49):e9005
pubmed: 29245280
Radiology. 1995 Mar;194(3):671-80
pubmed: 7862961
Exp Ther Med. 2015 Feb;9(2):523-526
pubmed: 25574227
J Clin Neurosci. 2009 Feb;16(2):341-3
pubmed: 19071022
J Clin Neurosci. 2011 Jan;18(1):138-40
pubmed: 20851606
J Neurol Sci. 1999 May 1;165(1):43-7
pubmed: 10426146
Neurosurg Rev. 2015 Apr;38(2):253-63; discussion 263-4
pubmed: 25468011
Neurosurgery. 2008 Oct;63(4):693-98; discussion 698-9
pubmed: 18824942
Neurosurg Rev. 2015 Apr;38(2):273-81; discussion 281
pubmed: 25516093
Mov Disord. 2007 Feb 15;22(3):437-9
pubmed: 17216644
Mov Disord Clin Pract. 2017 Mar 27;4(4):607-611
pubmed: 30363443
J Neurol Sci. 2014 Aug 15;343(1-2):211-4
pubmed: 24928082
Neurol Med Chir (Tokyo). 2013;53(4):224-7
pubmed: 23615412
Acta Neurochir Suppl. 2018;129:85-89
pubmed: 30171318
J Mov Disord. 2015 Sep;8(3):141-3
pubmed: 26413242
Acta Neurochir (Wien). 2019 Sep;161(9):1775-1781
pubmed: 31267189
Mov Disord. 2012 Nov;27(13):1690-3
pubmed: 23079935
Neurologist. 2019 Jul;24(4):132-135
pubmed: 31246722

Auteurs

Julia Velz (J)

Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
University of Zurich, Zurich, Switzerland.

Zsolt Kulcsar (Z)

University of Zurich, Zurich, Switzerland.
Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.

Fabian Büchele (F)

University of Zurich, Zurich, Switzerland.
Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.

Heiko Richter (H)

Department of Neurosurgery, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Luca Regli (L)

Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland, luca.regli@usz.ch.
University of Zurich, Zurich, Switzerland, luca.regli@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH